Printer Friendly

i"?Bruker collaborates with the University of Victoria-Genome British Columbia Proteomics Centre.

M2 EQUITYBITES-April 25, 2013-i" Bruker collaborates with the University of Victoria-Genome British Columbia Proteomics Centre(C)2013 M2 COMMUNICATIONS http://www.m2.com

Bruker, a manufacturer of analytical and medical instruments covering NMR, ESR, FT-IR, X-RAY spectroscopy, has collaborated with the University of Victoria-Genome British Columbia Proteomics Centre.

It was reported yesterday that the collaboration is aimed at developing and validating high-throughput assays. The assays are utilised to determine hemoglobin variants and diabetes risk, using Bruker's Matrix-Assisted Laser Desorption Ionisation (MALDI) Biotyper platform for clinical mass spectrometry and based on intellectual property developed at the UVic GBC Proteomics Centre.

The new Matrix-Assisted Laser Desorption Ionisation time-of-flight mass spectrometry based test for hbA1c and genetic hemoglobin variants is intended for use on the MALDI Biotyper platform is likely to provide specificity, accuracy, speed of analysis and cost per analysis.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDApril 25, 2013>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 25, 2013
Words:159
Previous Article:i"?BD Rx receives approval for BD Simplist Metoclopramide Injection.
Next Article:i"?Merck Canada to provide USD4m to Institute for Research in Immunology and Cancer - Commercialisation of Research.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters